Get the Stockscreener App
0.5616
4.56%
0.0245
Sangamo Therapeutics Inc stock is traded at $0.5616, with a volume of 4.18M.
It is up +4.56% in the last 24 hours and up +4.74% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.5371
Open:
$0.5395
24h Volume:
4.18M
Relative Volume:
0.81
Market Cap:
$130.95M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.7488
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-4.10%
1M Performance:
+4.74%
6M Performance:
-54.34%
1Y Performance:
-20.32%
1-Day Range:
$0.5202
$0.5712
1-Week Range:
$0.5202
$0.699
52-Week Range:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5616 | 131.81M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
What are the technical indicators suggesting about Sangamo Therapeutics Inc.Daily Trading Forecasts For Consistent Profits - jammulinksnews.com
How strong is Sangamo Therapeutics Inc. company’s balance sheetDaily Trading Strategy For Smart Trading - jammulinksnews.com
When is Sangamo Therapeutics Inc. stock expected to show significant growthAdvanced Screener Guidance From AI Tools - jammulinksnews.com
Is Sangamo Therapeutics Inc. stock overvalued or undervaluedMarket Forecast Opportunities Backed By Experts - jammulinksnews.com
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call - The Manila Times
Does Sangamo Therapeutics Inc. stock perform well during market downturnsReal Time Planner For Fast Growth - jammulinksnews.com
Has Sangamo Therapeutics Inc. formed a bullish divergenceOversold Bounce Stock Play Ideas Gain Attention - metal.it
Published on: 2025-07-30 16:12:38 - beatles.ru
Will Sangamo Therapeutics Inc. outperform the marketAI Trading Suggestions With Accuracy Focus Released - metal.it
Hunter Syndrome Treatment Market Exclusive Report with - openPR.com
How volatile is Sangamo Therapeutics Inc. stock compared to the marketAI Powered Updates From AI Tools - jammulinksnews.com
What is the dividend policy of Sangamo Therapeutics Inc. stockDiscover high-impact stocks for growth - jammulinksnews.com
What are the latest earnings results for Sangamo Therapeutics Inc.Free Stock Updates For 2025 - jammulinksnews.com
Published on: 2025-07-28 06:51:50 - jammulinksnews.com
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsSafe and Scalable Investment Tips - metal.it
What institutional investors are buying Sangamo Therapeutics Inc. stockHigh-return market picks - jammulinksnews.com
Published on: 2025-07-27 08:45:15 - metal.it
How Sangamo Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - metal.it
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - MSN
Is Sangamo Therapeutics Inc. a good long term investmentConsistent wealth multiplication - PrintWeekIndia
What drives Sangamo Therapeutics Inc. stock priceExceptional stock performance - PrintWeekIndia
What analysts say about Sangamo Therapeutics Inc. stockSky-high return potential - PrintWeekIndia
Sangamo Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - PrintWeekIndia
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):